The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Current Vascular Pharmacology

• Publication date

  2011-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/157016111795495503PMID 20807189
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer.

  2016cited by this paper
• Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib

  2013cited by this paper
• Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

  2010cited by this paper
• A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.

  2010cited by this paper
• VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.

  2010cited by this paper
• Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.

  2010cited by this paper
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

  2010cited by this paper
• Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.

  2010cited by this paper
• ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma.

  2010cited by this paper
• NF‐κB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro

  2009cited by this paper
• VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients (pts).

  2009cited by this paper
• New approaches to antidepressant drug design: cytokine-regulated pathways.

  2009cited by this paper
• Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.

  2009cited by this paper
• Phase 2 open‐label study of single‐agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B–endemic Asian population

  2009cited by this paper
• Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non–Small Cell Lung Cancer

  2009cited by this paper
• Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.

  2009cited by this paper
• Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.

  2009cited by this paper
• Hypertension as a surrogate marker for the activity of anti-VEGF agents.

  2009cited by this paper
• Endothelial Progenitor Cells Bind and Inhibit Platelet Function and Thrombus Formation

  2009cited by this paper
• Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

  2009cited by this paper
• A phase II study of aflibercept (VEGF trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: A study of the Princess Margaret Hospital Phase II Consortium.

  2009cited by this paper
• Reorganisation of the dendritic actin network during cancer cell migration and invasion.

  2008cited by this paper
• A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer

  2008cited by this paper
• VEGF promotes vascular sympathetic innervation.

  2008cited by this paper
• Heart failure associated with sunitinib malate

  2008cited by this paper
• Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor

  2008cited by this paper
• Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

  2008cited by this paper
• A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.

  2008cited by this paper
• Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.

  2008cited by this paper
• Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial

  2008cited by this paper
• A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: preliminary results

  2008cited by this paper
• Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

  2008cited by this paper
• Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)

  2008cited by this paper
• Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer

  2008cited by this paper
• A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial

  2008cited by this paper
• Cancer: Tuning anti-angiogenesis

  2008cited by this paper
• A phase II study of sorafenib in metastatic thyroid carcinoma

  2008cited by this paper
• Home blood-pressure monitoring in patients receiving sunitinib.

  2008cited by this paper
• Abstract 5564: Sequencial Activation of VEGF/Flk-1/MKK2/NFkappaB Signaling in Ischemic Preconditioning Induced Neovascularization: A Study with Flk-1+/- and MKK2-/- Knockout Mice

  2008cited by this paper
• Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

  2008cited by this paper
• Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.

  2008cited by this paper
• Phase 2 study of sunitinib in refractory thyroid cancer

  2008cited by this paper
• Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

  2008cited by this paper
• Phase II trial of sorafenib in advanced thyroid cancer.

  2008cited by this paper
• Sodium channel blockers.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC)

  2007cited by this paper
• Roles for VEGF in the adult.

  2007cited by this paper
• Mechanisms of adverse effects of anti-VEGF therapy for cancer

  2007cited by this paper
• A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

  2007cited by this paper
• Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.

  2007cited by this paper
• Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.

  2007cited by this paper
• Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

  2007cited by this paper
• Non-neoplastic Renal Diseases are Often Unrecognized in Adult Tumor Nephrectomy Specimens: A Review of 246 Cases

  2007cited by this paper
• Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium

  2007cited by this paper
• Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

  2007cited by this paper
• Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)

  2007cited by this paper
• DRUG EFFECTS ON THE MECHANICAL PROPERTIES OF LARGE ARTERIES IN HUMANS

  2007cited by this paper
• A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers

  2007cited by this paper
• A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.

  2007cited by this paper
• Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)

  2007cited by this paper
• Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.

  2007cited by this paper
• Neuropilin-1 Binds to VEGF121 and Regulates Endothelial Cell Migration and Sprouting*

  2007cited by this paper
• Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors

  2007cited by this paper
• Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions

  2007cited by this paper
• Microalbuminuria and cardiovascular disease.

  2007cited by this paper
• Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial

  2007cited by this paper
• Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.

  2007cited by this paper
• Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

  2007cited by this paper
• 859 UNCONTROLLED CONFIRMATORY TRIAL OF SINGLE-AGENT SORAFENIB IN JAPANESE PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

  2007cited by this paper
• Expression of vascular endothelial growth factor (VEGF) in normal oral mucosa, oral dysplasia and oral squamous cell carcinoma.

  2007cited by this paper
• Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

  2007cited by this paper
• Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.

  2007cited by this paper
• The relationship between venous hypertension and expression of vascular endothelial growth factor: hemodynamic and immunohistochemical examinations in a rat venous hypertension model.

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.

  2007cited by this paper
• Antenatal antioxidant prevents adult hypertension, vascular dysfunction, and microvascular rarefaction associated with in utero exposure to a low-protein diet.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer

  2007cited by this paper
• Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

  2007cited by this paper
• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

  2007cited by this paper
• Lessons from phase III clinical trials on anti-VEGF therapy for cancer

  2006cited by this paper
• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

  2006cited by this paper
• AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.

  2006cited by this paper
• A phase I study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in combination with gemcitabine (GEM) in patients (pts) with advanced pancreatic cancer.

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• [Rationale of antiangiogenic therapy].

  2006cited by this paper
• Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy.

  2006cited by this paper
• Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis.

  2006cited by this paper
• Semaphorin 3d promotes cell proliferation and neural crest cell development downstream of TCF in the zebrafish hindbrain

  2006cited by this paper
• Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

  2006cited by this paper
• Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients

  2006cited by this paper
• Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

  2006cited by this paper
• Expression of Hypoxia-inducible Factor-1 and Vascular Endothelial Growth Factor in Response to Venous Hypertension

  2006cited by this paper
• Vascular Endothelial Growth Factor Blockade Promotes the Transition From Compensatory Cardiac Hypertrophy to Failure in Response to Pressure Overload

  2006cited by this paper
• Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas.

  2006cited by this paper
• A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer.

  2006cited by this paper
• Vascular endothelial growth factor upregulates expression of ADAMTS1 in endothelial cells through protein kinase C signaling.

  2006cited by this paper
• Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer.

  2006cited by this paper
• VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis

  2006cited by this paper

• Cardiovascular toxicity of Fruquintinib in patients with colorectal and other cancers: a systematic review and meta-analysis

  2025cites this paper
• Preclinical evaluation of tissue-engineered vascular grafts with biodegradable components: assessing the effectiveness of animal models from rats to primates

  2025cites this paper
• Advancements and emerging trends in ophthalmic anti-VEGF therapy: a bibliometric analysis

  2024cites this paper
• Association of Variants in Vascular Endothelial Growth Factor A Gene and VEGFA Serum Levels with the Risk of Primary Ovarian Insufficiency: A Case-Control Study

  2021cites this paper
• bFGF and SDF-1α Improve In Vivo Performance of VEGF-Incorporating Small-Diameter Vascular Grafts

  2021cites this paper
• Study on the Mechanism of Hypertension Caused by Sorafenib in Liver Cancer-Bearing Rats Based on VEGF Signal Pathway

  2021cites this paper
• Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.

  2020cites this paper
• The relationship of endothelial dysfunction and metabolic manifestations of obesity

  2020cites this paper
• Взаимосвязь эндотелиальной дисфункции и метаболических проявлений ожирения

  2020cites this paper
• Arterial hypertension in patients under antineoplastic therapy: a systematic review

  2019cites this paper
• Association of VEGFA variants with altered VEGF secretion and type 2 diabetes: A case‐control study

  2018cites this paper
• Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study

  2018cites this paper
• Obesity and functional state of kidney depends on VEGF polymorphism

  2018cites this paper
• IN SILICO АНАЛИЗ АФФИННОСТИ ЧЕЛОВЕЧЕСКИХ VEGF, bFGF, SDF-1α К

  2018cites this paper
• Effect of oral niacin on central retinal vein occlusion

  2017cites this paper
• Relationship between skin blood flow regulation mechanisms and vascular endothelial growth factor in patients with metabolic syndrome

  2017cites this paper
• Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System

  2017cites this paper
• MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib.

  2016cites this paper
• The Potential Role of Nitric Oxide in Halting Cancer Progression Through Chemoprevention

  2016influential citation
• The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-κB genes expression.

  2016cites this paper
• Anti-VEGF-induced hypertension and cancer outcomes: translating research into clinical practice

  2016influential citation
• Conjugation with RGD Peptides and Incorporation of Vascular Endothelial Growth Factor Are Equally Efficient for Biofunctionalization of Tissue-Engineered Vascular Grafts

  2016cites this paper
• Association study of C936T polymorphism of the VEGF gene and the C242T polymorphism of the p22phox gene with diabetes mellitus type 2 and distal diabetic polyneuropathy.

  2015cites this paper
• Apigenin inhibits TGF‐β‐induced VEGF expression in human prostate carcinoma cells via a Smad2/3‐ and Src‐dependent mechanism

  2014cites this paper
• Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study

  2014cites this paper
• Investigação dos polimorfismos C936T do gene VEGF e C242T do gene p22phox no diabetes mellitus tipo 2 e relação com a polineuropatia distal diabética

  2014cites this paper
• The contribution of VEGF signalling to fostamatinib‐induced blood pressure elevation

  2014influential citation
• Vascular endothelial growth factor from embryonic status to cardiovascular pathology.

  2014cites this paper
• Disparate effects of single endothelin A and B receptor blocker therapy on the progression of renal injury in advanced renovascular disease

  2013cites this paper
• Erratum to: Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines

  2013cites this paper
• Increase in peripheral blood mononuclear cell Toll-like receptor 2/3 expression and reactivity to their ligands in a cohort of patients with wet age-related macular degeneration

  2013cites this paper
• Vascular endothelial growth factor regulates adult hippocampal cell proliferation through MEK/ERK- and PI3K/Akt-dependent signaling.

  2012cites this paper
• Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines

  2012cites this paper
• Circulating Progenitor Cell Therapeutic Potential Impaired by Endothelial Dysfunction and Rescued by a Collagen Matrix

  2012cites this paper
• Modulating angiogenesis through the Th1 and Th2 immune switch

  2011cites this paper
• DNA Repair, Cancer and Cancer Therapy

  2011cites this paper
• Will VEGF Trap-Eye reduce the treatment burden in neovascular age-related macular degeneration?

  2011cites this paper